https://bgj398inhibitor.com/ev....aluation-of-serumuri
Significant difference in myelosuppression involving the teams was likely due to the combination of TMP-SMX effect on PID patients rather than the disease or even the drug itself. Major protected deficiency (PID) patients are at higher risk of building myelosuppression secondary to TMP-SMX prophylaxis (especially ANC) researching to immune-competent customers or any other PID patients which would not obtain prophylactic TMP-SMX. Future large
Like
Comment
Share
